Which test first — auscultation, X-ray, NT-proBNP or echo?

Follow the ladder: auscultation flags a murmur, thoracic X-ray screens for heart enlargement and fluid, NT-proBNP separates cardiac from respiratory signs with one blood draw, and echocardiography is the gold standard that characterizes the disease. NT-proBNP is the cheapest triage step that prevents sending every coughing dog to a cardiologist.

Why screen at-risk breeds if they look healthy?

Because the diseases are silent until decompensation. Cavaliers, Dachshunds and Chihuahuas for MMVD; Maine Coons and Ragdolls for HCM — these breeds develop disease years before clinical signs. A rising NT-proBNP trend across a year catches the disease while therapy is cheap and effective, not after the first bout of heart failure.

Canine & Feline Heart Disease Testing: Complete Guide

Q: What is the most common heart disease in dogs and cats?

In dogs it is myxomatous mitral valve disease (MMVD) — up to 85% of small-breed dogs show the valve lesion by 13 years of age. In cats it is hypertrophic cardiomyopathy (HCM), found in roughly 15% of random-bred cats. The two diseases need different testing strategies: dogs are screened by auscultation then NT-proBNP, cats by NT-proBNP first because their murmurs are less reliable.

Q: Can a normal NT-proBNP rule out heart disease?

Mostly, but not absolutely. In dogs a value above ~1158 pmol/L is 85.5% sensitive and 81.3% specific for congestive heart failure; in cats a cutoff of 265 pmol/L is 90% sensitive and 88% specific. A low value makes clinically significant heart disease unlikely, but early MMVD or HCM with minimal wall stress can still read normal — which is why at-risk breeds get serial testing, not one snapshot.

Q: Does a heart murmur mean heart disease?

Not always, and the reverse is more dangerous: many cats with HCM have no murmur at all, and a soft early MMVD murmur can be missed on a rushed auscultation. A murmur is a reason to test, not a diagnosis. In cats especially, rely on NT-proBNP and echo rather than waiting for a loud murmur.

Q: How fast is heart testing in-house?

NT-proBNP returns in 10–20 minutes on a quantitative immunofluorescence analyzer like the Migibio FIA680 or FIA880. Auscultation is instant, X-ray is minutes, and only echocardiography needs a specialist or a trained operator. The first three steps can happen entirely within one consult.

TL;DR — Heart disease is the leading cause of acquired cardiac death in older dogs and cats, and it is almost perfectly silent until the day the patient decompensates. The two species fail differently: dogs get myxomatous mitral valve disease (MMVD) — up to 85% of small-breed dogs show the valve lesion by age 13 — while cats get hypertrophic cardiomyopathy (HCM) — present in roughly 15% of random-bred cats. The testing ladder is the same for both: auscultation → thoracic X-ray → NT-proBNP → echocardiography. NT-proBNP is the pivot: one blood draw separates “heart” from “lungs” in 10–20 minutes. The trap most practices miss is that a normal NT-proBNP does not rule out early disease — the trend across a year matters more than any single number.

In Plain Terms

A failing heart does not announce itself. A dog with early mitral valve disease wags and runs normally for years while the valve leaks a little more each month. A cat with thickening heart muscle can seem perfectly healthy until a blood clot or sudden collapse. By the time there are obvious signs — coughing, fast breathing, exercise intolerance — the disease is advanced.

That is why heart testing is built around catching the disease before it catches the patient. The tools are cheap and fast; the hard part is remembering to use them on patients who look fine.

The Two Species Fail Differently

This is the single most important concept in veterinary cardiology, and it determines everything about how you test.

	Dogs	Cats
Most common disease	MMVD (leaky mitral valve)	HCM (thickened heart muscle)
Second	DCM (dilated heart, large breeds)	RCM (restrictive, less common)
Typical patient	Small breeds >8 years	Any cat, often middle-aged
Best first signal	Heart murmur (usually audible)	NT-proBNP (murmurs unreliable)
Prevalence headline	85% of small dogs by 13 years	~15% of cats

Why this matters for testing: in a dog, a murmur is a reliable early flag, so auscultation comes first and NT-proBNP confirms. In a cat, up to half of HCM cats have no murmur or only a soft, intermittent one, so you lead with NT-proBNP and let echo confirm. A practice that tests cats the way it tests dogs — waiting for a loud murmur — will miss a large fraction of feline heart disease.

The Silent-Disease Problem

Three numbers explain why heart disease slips through routine care:

85% — the share of small-breed dogs showing MMVD valve lesions by age 13. Yet only about 30% ever progress to advanced disease, and the progression is unpredictable. So the challenge is not finding the lesion, it is knowing which of the many affected dogs will decompensate.
~15% — the prevalence of HCM in random-bred cats, with breed-specific peaks: 10.1% in Maine Coons, 16.7% in Bengals, and a published 2.9% in Ragdolls (higher in other cohorts). HCM is the most common cause of feline sudden death and arterial thromboembolism.
1.5× — how much more common MMVD is in males than females. Small-breed, male, middle-aged-to-senior is the highest-yield profile to screen.

The clinical consequence: heart disease is a numbers game. You will see far more patients with the disease than with signs of it, so screening protocols — not symptom-triggered workups — are what actually catch it.

The Testing Ladder

Step 1 — Auscultation (30 seconds, free)

A left apical systolic murmur is the classic MMVD sign; it often precedes heart failure by years. In cats, a gallop rhythm or arrhythmia is more meaningful than a murmur. Limitation: auscultation is operator-dependent, and a soft murmur in an anxious dog or a panting cat is easy to miss.

Step 2 — Thoracic X-ray (minutes, low cost)

Screens for left atrial enlargement (a key MMVD progression marker), general cardiomegaly, and pulmonary edema or pleural effusion. A vertebral heart score (VHS) above ~10.5–11.5 in dogs signals enlargement worth investigating. Limitation: X-ray shows shape and fluid, not function.

Step 3 — NT-proBNP (10–20 minutes, one blood draw)

The biomarker that does the triage. When heart muscle stretches under pressure or volume overload, it releases NT-proBNP. The reference frame:

Species	Cut-off	What it separates	Performance
Dog	~201 pmol/L	Cardiac vs primary respiratory	—
Dog	~1158 pmol/L	CHF vs non-cardiac dyspnea	85.5% sens / 81.3% spec
Cat	~265 pmol/L	CHF vs respiratory disease	90% sens / 88% spec

Two hard rules: (1) cut-offs are platform-dependent — published dog values span a ~2× range across assays, so use the interval validated for your analyzer, never a memorised number; (2) NT-proBNP is cleared by the kidneys, so an azotemic cat reads falsely high — always interpret it alongside creatinine and SDMA.

Step 4 — Echocardiography (gold standard)

Characterizes the disease: valve degeneration vs dilated vs hypertrophic, chamber size, systolic function, and — critically — whether the left atrium has enlarged enough to justify starting pimobendan in MMVD (the B1→B2 decision). Echo requires equipment and a trained operator; it is the confirmatory step, not the screening step.

The B1→B2 Decision That Divides Cardiology

MMVD is staged A through D under the ACVIM system, and the single most consequential clinical decision is B1 versus B2 — whether an asymptomatic dog with a murmur and no heart enlargement needs lifelong medication.

Stage B1 — murmur present, no radiographic/echocardiographic enlargement. Consensus: no treatment, just monitoring.
Stage B2 — murmur plus significant left heart enlargement. The EPIC trial showed pimobendan delays the onset of heart failure in this group, which is why 93% of surveyed practitioners correctly withhold medication from B1 dogs but start it once enlargement is confirmed.

The controversy is where the B2 line sits — it depends on echocardiographic left-atrial and left-ventricular measurements that vary by operator and breed. This is exactly where a quantitative NT-proBNP trend earns its keep: a climbing value across serial visits is objective, independent evidence of progression that supports the B1→B2 call without a specialist echo on every recheck.

Feline HCM: The Disease That Hides

HCM thickens the left ventricular wall, reducing chamber size and diastolic filling. The dangers are congestive heart failure and arterial thromboembolism (a saddle thrombus that causes sudden hind-limb paralysis). Two testing realities set cats apart from dogs:

The murmur is a poor screening tool. Many HCM cats have no murmur, or only a transient one. NT-proBNP is the better first-line screen: a value above 265 pmol/L carries a 92% positive predictive value and 85% negative predictive value for distinguishing cardiac from respiratory dyspnea in cats.
Genetics help but don’t settle it. Two MYBPC3 mutations are known — A31P in Maine Coons and R820W in Ragdolls. A positive test confirms high risk, but a negative test does not rule out HCM: there are undiscovered mutations and sporadic cases, so an at-risk cat still needs periodic echo screening. In screened Maine Coons, the A31P mutation incidence exceeds 30%.

When to Test: Screening Indications

Screen a patient when any of these apply — before symptoms, not after:

Breed risk: Cavalier King Charles Spaniel, Dachshund, Chihuahua, Poodle, small terriers (MMVD); Doberman, Boxer, Great Dane (DCM); Maine Coon, Ragdoll, Bengal, Sphynx (HCM).
Age: any small-breed dog over ~8 years, any middle-aged-to-senior cat.
The ambiguous sign: a cough that “won’t clear,” exercise intolerance, a fast resting respiratory rate at home (>30–40 breaths/min in a sleeping cat is a red flag).
Pre-anesthesia: older patients with a murmur or breed risk before any procedure.
Known disease: serial NT-proBNP to monitor progression and therapy response.

What Cardiac Testing Is Worth to a Clinic

Heart testing is one of the cleanest medicine-plus-revenue cases in small-animal practice:

Same-visit triage. The coughing senior or fast-breathing cat gets an answer in the consult, not a next-day reference-lab call — which also means the owner doesn’t go home worried overnight.
It justifies or spares the echo. A high NT-proBNP makes the case for referral; a low one spares a healthy-looking pet an expensive workup. Either way the decision is documented and defensible.
It builds a monitoring relationship. Cardiac patients return for serial NT-proBNP — each recheck is a billable visit, and a climbing value is an objective reason to escalate care.

Beyond MMVD and HCM: The Wider Cardiac Map

MMVD (dog) and HCM (cat) dominate, but they are not the whole map:

Disease	Species	Test	Notes
MMVD	Dog	Auscultation → NT-proBNP → echo	85% of small dogs by 13
DCM	Dog (large breeds)	Echo + NT-proBNP	Dobermans, Boxers, Great Danes
HCM	Cat	NT-proBNP → echo	~15% of cats
Congenital	Puppy/kitten	Echo	Murmur in a young animal

The screening protocol is the same shape across all of them: auscultation flags, NT-proBNP quantifies the strain, echo characterises the disease, and serial NT-proBNP tracks progression. A rising NT-proBNP trend across annual screens — even inside the normal range — is the earliest warning that a progressor is emerging. See heart screening for the full protocol.

How the Test Runs

Draw serum or plasma (check kit whole-blood compatibility).
Load the NT-proBNP cartridge into a quantitative immunofluorescence analyzer.
The analyzer incubates and quantifies the fluorescent signal against a stored calibration curve.
Read a numeric pmol/L result in 10–20 minutes — storable, comparable to the reference range, and, most importantly, comparable to the patient’s previous values.

Related products: Canine NT-proBNP Test · Feline NT-proBNP Test · FIA680 Analyzer · FIA880 Analyzer

FAQ

What is the most common heart disease in dogs and cats?

2 species, 2 diseases — dogs get MMVD (up to 85% of small breeds by age 13), cats get HCM (~15% of random-bred cats). Dogs are screened by auscultation then NT-proBNP; cats by NT-proBNP first, because their murmurs are less reliable.

Which test comes first?

4 steps in order — auscultation flags a murmur, X-ray screens for enlargement and fluid, NT-proBNP separates cardiac from respiratory signs in 10–20 minutes, and echo characterizes. NT-proBNP is the cheapest step that prevents sending every coughing dog to a cardiologist.

Can a normal NT-proBNP rule out heart disease?

Not absolutely — a dog above ~1158 pmol/L is 85.5% sensitive for CHF; a cat above 265 pmol/L is 90% sensitive. A low value makes significant disease unlikely, but early MMVD or HCM with minimal wall stress can still read normal — so at-risk breeds get serial testing, not one snapshot.

Does a heart murmur mean heart disease?

Not always — and the reverse is the danger: up to half of HCM cats have no murmur at all, and a soft early MMVD murmur is easy to miss. A murmur is a reason to test, not a diagnosis — and 85% of small dogs show MMVD by age 13 whether or not you hear it.

How fast is heart testing in-house?

NT-proBNP returns in 10–20 minutes on an immunofluorescence analyzer; auscultation is instant and X-ray is minutes. Only echo needs a specialist — the first three steps fit one consult.

Why screen at-risk breeds that look healthy?

Because the diseases are silent until decompensation — MMVD hits 85% of small dogs by 13 and HCM ~15% of cats. A rising NT-proBNP trend across a year catches the disease while therapy is cheap, not after the first bout of heart failure.

Key Takeaways

Know the species split — dogs fail by MMVD (85% of small breeds by 13), cats by HCM (~15% prevalence). Test dogs by murmur first, cats by NT-proBNP first, or you’ll miss the feline cases that never develop a loud murmur.
The ladder is cheap and fast — auscultation (30s) → X-ray (minutes) → NT-proBNP (10–20 min) → echo. The first three happen in one consult; only echo needs a specialist.
NT-proBNP is the pivot, not the verdict — dog >1158 pmol/L (85.5% sens), cat >265 pmol/L (90% sens) separates heart from lungs. But a normal value doesn’t rule out early disease — the trend beats the single number.
The B1→B2 call is where money and medicine meet — 93% of practitioners correctly withhold meds from B1 dogs; a climbing quantitative NT-proBNP is the objective evidence that supports starting pimobendan at B2 without a specialist echo every visit.
Genetics screen, they don’t diagnose — Maine Coon A31P and Ragdoll R820W confirm risk (A31P incidence >30%), but a negative test doesn’t rule out HCM. At-risk cats still need periodic echo, not a one-time gene swab.

References

Keene BW, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019. PMID 31389076
Payne JR, et al. Population characteristics and survival in cats with hypertrophic cardiomyopathy. J Vet Intern Med. 2010. PMID 20840126
Fox PR, et al. NT-proBNP in feline respiratory distress. J Vet Intern Med. 2011;25(5):1010–1016. PMID 21848947
Boswood A, et al. NT-proBNP cut-offs in dogs with cardiac vs respiratory disease. PMID (see IDEXX Cardiopet proBNP literature)
Meurs KM, et al. A substitution mutation in the myosin binding protein C gene in Ragdoll HCM. Genomics. 2007;90(2):261–264. PMID 17553619
Meurs KM, et al. A31P MYBPC3 mutation in Maine Coon HCM. Hum Mol Genet. 2005. PMID 15829503
IRIS (International Renal Interest Society) CKD staging guidelines: https://www.iris-kidney.com/

This content is for educational and product-selection purposes only. It is not a substitute for veterinary diagnosis — any animal with suspected heart disease should be evaluated by a veterinarian. Reference ranges are platform- and population-dependent; always use the intervals validated for your specific analyzer. Product specifications are as published by Migibio (Guangzhou Magic Biotech Co., Ltd.) and may change.